Preclinical studies have shown that tau-targeted PROTACs can reduce tau aggregation, one of the pathological hallmarks of AD, and alpha-synuclein-recruited PROTACs have shown potential in animal models of Parkinson’s disease [71]. This evidence concerns the gene MAPT and Parkinson disease.